INA P. KAGEL
Law Offices
1801 Century Park East, Suite 1201
Los Angeles, CA 90067
TELEPHONE: (310) 860-9975
E-MAIL: ikagel@earthlink.net

October 9, 2020

OTC Markets Group
304 Hudson Street
Second Floor
New York NY 10013

Re: Zicix Corporation

Ladies and Gentlemen:

This office acts as counsel to Zicix Corporation, a Nevada corporation (hereinafter the "Company" or the "Issuer"):

1. OTC Markets Group is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available within the meaning for Rule 144(c)(2) under the Securities Act of 1933, as amended.

2. I am a United States resident, and have been retained by the Issuer as counsel, including but not limited to the rendering of this letter and other related business and securities matters. My firm owns 1,000,000 shares of common stock of the Company which were issued in November, 2018 for services. I have no agreement or arrangement to receive additional shares.

3. I have examined such corporate records and other documents and such questions of law as I consider necessary or appropriate for purposes of rendering this letter.

4. I am authorized to practice law in the State of California. The opinions expressed herein are limited to matters concerning the laws of the States of California and Nevada and the federal laws of the United States. I express no opinion as to the laws of any other jurisdiction. This letter does not rely on the work of other counsel.

5. I am permitted to practice before the Securities and Exchange Commission and have not been prohibited or disbarred from practice, in any respect, before that agency. I am not currently, nor have ever been suspended or barred from practicing in any state or jurisdiction, nor charged in a civil or criminal proceeding, I am not currently nor have I ever been the subject of an investigation, hearing or proceeding by the SEC, the Commodity Futures Trading Commission, the Financial Industry Authority, or any other federal or state regulatory authority.

6. In connection with this letter, I have (i) investigated the questions of law; (ii) examined originals or certified, conformed or reproduction copies of documents, and other such agreements, instruments, documents and records of the Issuer, such certificates of public record and such other documents; and (iii) received such information from officers and representatives of the Issuer as I have deemed necessary or appropriate for the purposes of this letter. In all such examinations, I have assumed the legal capacity of all natural persons, the genuineness of all signatures, and the authenticity of original and certified documents submitted to me and the conformity to original documents of all copies submitted to me as conformed or reproduction copies. As to various questions of fact relevant to the opinions expressed herein, I have relied upon, and assume the accuracy of, representations and warranties contained in the documents and certificates and oral or written statements and other information of or from representatives of the Issuer and others.

7. In the preparation of this letter, I have reviewed the Supplemental Information-Disclosure Statement for the Six Months Ended June 30, 2020, Quarterly Report-Financial Statements for the Six Months Ended June 30, 2020, Supplemental Information-Disclosure Statement for the Three Months Ended March 31, 2020, Quarterly Report-Financial Statements for the Three Months Ended March 31, 2020, Supplemental Information- Disclosure Statement for the Year Ended December 31, 2019, Annual Report-Financial Statements for the Year Ended December 31, 2019, all filed with OTC Markets October 5-8, 2019, Information & Disclosure Statement and Annual Report for the period ending December 30, 2018 filed with OTC Markets on March 15, 2019 and the Supplemental Information – 2018 Financial Statement Amended filed on April 7, 2019. I am of the opinion that these documents are accurate, up to date, and contain the most current information available on the Issuer. I have also reviewed other materials filed with OTC Markets on March 10 and March 15, 2019, covering prior periods.

8. To the best of my knowledge, as of the date of this letter, the information referred to above (the "Information") (i) constitutes "adequate current public information" concerning the common stock of the Issuer (the "Securities") and the Issuer, and "is available" within the meaning of Rule 144(c)(2) of the Securities Act, (ii) includes all information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the OTC Markets Group Guidelines for Providing

Adequate Public Current Information, which are located on the internet at www.OTCMarkets.com, and (iv) has been posted through the OTC Disclosure & News Service.

9. The persons responsible for preparation of the financial statements contained in the Information are Billie J. Allred, CPA and Liam Tynan, who has more than 20 years of experience with public companies. The financial statements of the Company were not audited or reviewed.

10. The Issuer's transfer agent is TransferOnLine, Inc. The Issuer's transfer agent is registered with the Securities and Exchange Commission. I have confirmed the number of outstanding shares set forth in the Information with the transfer agent. The number of outstanding shares of common stock as of this date is 681,781,004.

11. I have (i) personally conferred telephonically with management of the Issuer and members of its Board of Directors, (ii) reviewed the Information published by the Issuer through the OTC Disclosure & News Service, and (iii) discussed the Information with management and the Board of Directors of the Issuer.

12. To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither the Issuer, any 5% holder of the securities in the Issuer, nor any members of my firm are currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

13. The opinions expressed herein are solely for the benefit of the OTC Markets Group, which is entitled to reply upon this letter, and may not be relied on in any manner or for any purpose by any other person or entity and may not be quoted in whole or in part without my prior written consent. I hereby grant OTC Markets Group full and complete permission and rights to publish this letter through the OTC Disclosure & News Service for viewing by the public and regulators.

14. The opinions expressed herein are given as of the date hereof, and I undertake no obligation to supplement this letter if any applicable laws change after the date hereof or if I become aware of any facts that might change the opinions expressed herein after the date hereof or for any other reason.

Very Truly Yours,

Ina P. Kagel

Ina P. Kagel